Retrospective, External Comparator Study of Lazertinib as the 2nd-Line Treatment in Patients With EGFR Mutation+ NSCLC

Sponsor
Yuhan Corporation
Study ID
NCT05862194
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Lazertinib — DRUG
    Patients who previously received first or second-generation EGFR-TKI treatment, and who started administrating Lazertinib during the index period
  • Platinum-based Chemotherapy — DRUG
    Patient who started administering platinum-based chemotherapy after prior first or second-generation EGFR-TKI treatment during the index period

Study Details

This retrospective, external comparator study for Lazertinib aims to assess the real-world effectiveness of Lazertinib as the second-line treatment versus platinum-based chemotherapy in patients with epidermal growth receptor sensitizing mutation-positive, locally advanced or metastatic Non-small Lung cancer.

Key Dates

First listed
May 17, 2023
Start date
Jun 1, 2015
Status verified
Aug 2023
Primary completion
Apr 30, 2022
Completion
Mar 20, 2023

Study Design

Enrollment
534 participants (actual)

Arms

  • Arm: Lazertinib
  • Arm: Platinum-based Chemotherapy

Primary Outcome Measure

Comparative evaluation of (real-world:rw) Progression-free survival (PFS) between patients receiving Lazertinib versus Platinum-based Chemotherapy [ Time Frame: Up to 64 months ]

Find similar trials

Nationwide
Lung cancer trialsOncology trialsLung oncology trialsLung disease trials

Related Studies